Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

NCT00701103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Multiple Myeloma

Interventions

DRUG: Dalotuzumab

Sponsor

Merck Sharp & Dohme LLC